

 YURiA-PHARM

GMP



LIST OF CONTENTS:

INFUSION THERAPY

REOSORBILACT®	8
LATREN®	8
SODA-BUFER®	9
XYLAT®	9
TIVORTIN®	10
TIVORTIN® ASPARTATE	10
GiK®	11
HEKODES®	11
SORBILACT®	12
AMINOCAPROIC ACID, sol. 5%	12

SIMPLEX INFUSION SOLUTIONS

SODIUM CHLORIDE sol. 0,9%	13
GLUCOSE sol. 5%	13
WATER FOR INJECTION	13
RINGER'S sol.	14
RINGER'S-LACTATE sol.	14
SODIUM HYDROCARBONATE sol. 4%	14
MANNIT, 15%	15
POLYGLUCINUM	15
RHEOPOLYGLUCINUM	15

ANTISEPTICS

DECASAN®	16
HOROSTEN®	16

ANTIBIOTICS

LEFLOCIN®	17
LEFLOCIN® 750	17
BIGAFLOXIN®	18
OFLOXACIN	18
MAXICIN®	19
SOLUSEPTOL®	19
ORNIGIL®	20
CIPROFLOXACIN	20

CARTILAGE MODIFYING DRUGS

HYALUAL®-ARTRO	21
----------------	----

ORAL SOLUTIONS

LACTUVIT®	22
TIVORTIN® ASPARTATE	23

CLINICAL NUTRITION

AMINOL®	27
GLUXYL®	27

IRRIGATION SOLUTIONS

TURUSOL®	30
DECASAN® - CYTOCLIN®	30
CYTOCLIN®	31

TUBERCULOSIS TREATMENT

ISONIAZID syrup	24
RIFONAT®	24
INBUTOL®	25
PASKONAT®	25

ANTIVIRAL DRUGS

AKK®	28
------	----

ACCESSORIES FOR INFUSION THERAPY

SOLUVEN®	32
SYRINGES OF YURIA- PHARM WITH TWO NEEDLES	33
I.V. SETS OF YURIA PHARM (PS AND PB)	33

ANTI-PROTOZOAL DRUGS

METRONIDAZOLE	26
---------------	----

ANTIFUNGAL DRUGS

FLUCONAZOLE	29
FLUCONAZOLE 400 mg	29

FOR NOTES

34 - 35

ANESTHETICS

NOVOCAINE, sol. 0,25%, 0,5%	26
-----------------------------	----



«YURiA-PHARM» – dynamically growing company

Founded in 1998, «YURiA-PHARM» focused its efforts on production of infusions and as of today is a leading infusion manufacturer not only in Ukraine, but also in CIS. We supply medical facilities with more than 100 items of blood- and plasma substitute solutions, original infusion drugs, antibiotics, fungicidal drugs, syrups, antiseptics, parenteral nourishment preparations, anti-tuberculosis drugs, syringes, I.V. sets. Our product line sums up to more than 40 infusions, completely covering the needs of medical facilities in infusion therapy. Annual turnover of the company exceeds 60 mln bottles.

«YURiA-PHARM» confidently takes in the leading position in the export markets

We deliver our products to Russia, Moldova, Kazakhstan, Uzbekistan, Azerbaijan, Tajikistan, Kirgizia, Turkmenistan and Georgia. More than 100 items are now being registered for usage in different countries and the number is continuously growing.

In 2008 «YURiA-PHARM» Corporation has received a Certificate of compliance to international quality management standards ISO 9001 (9001:2009). In 2011 «YURiA-PHARM» Corporation has completed GMP certification.

«YURiA-PHARM» total headcount is constantly growing and at the moment exceeds 800, 2/3 of them being involved in production and R&D.

«YURiA-PHARM» – a wide range of popular original and generic infusion preparations

Our company produces a number of preparations (original and generic), which are not produced in CIS countries – REOSORBILACT[®], SORBILACT[®], DECASAN[®], HOROSTEN[®] etc. For instance, REOSORBILACT[®] (30% of total distribution of the preparations included in B 05 ATC code (B05 - Blood substitutes and perfusion solutions) and SORBILACT[®] constitute a basis of infusion therapy in Ukraine. They have completely replaced polyvinylpyrrolidone preparations (such as Hemodez, Neohemodez etc.) prohibited in many European and other countries, and restricted dextran preparations.

In our portfolio we also have unique cosmetological treatments – HYALUAL[®] (an anti-age therapy, helps keep skin young and healthy for a long time), cartilage modifying injectable drug – HYALUAL[®]-ARTRO – unique innovative cartilage protective preparation of new generation. It is an effective combination of hyaluronic acid and sodium succinate for treatment of osteoarthritis.

«YURiA-PHARM» – appreciated by the physicians and the scientific medical community

We cooperate intensively with many research institutions in the field. For the first time in CIS, in collaboration with Blood Pathology and Transfusion Medicine Institute of Ukraine's Academy of Medical Science, we have developed a group of complex multifunctional infusion solutions – REOSORBILACT®, SORBILACT®, XYLAT®, which today represent s basis of a new direction in internal medicine – Low-volume infusion therapy. Our corporation conducts an intensive research of the new preparations and also examines more deeply the capacity of the existing ones. We make large investments in Research & Development and prove the quality and efficiency of our preparations according to the requirements of the “case-based medicine”.

«YURiA-PHARM» – constant improvement of production according to market requirements

Keeping in mind constant enhancing of quality and accessibility of treatment, we improve the presentations and dosages of the preparations on a permanent basis.

At the moment our products are released in 9 forms, including prefilled syringes, nebulas, bags for irrigation solutions, polypropylene bags, PVC bags, glass bottles, plastic bottles, tablets.

«YURiA-PHARM» – a right hand of any physician

Our preparations accelerate the patients' recovery due to their higher efficiency, considerable decrease of complications and minimization of side-effects. Numerous reputable medical investigations prove a visible time saving in stationary treatment and higher therapy comfort level. These factors allow reducing the treatment cost and increasing an average annual bed turnover.

«YURiA-PHARM» – a reliable and advantageous partner

According to «YURiA-PHARM» long experience, practical usage of its preparations enhances an overall image both of a medical facility and of the physician.

Uncompromising quality and reasonable pricing have made our preparations bestsellers in Ukraine and CIS and we have every reason to expect similar success in other countries.



«YURiA-PHARM» – some short facts:

- leader in production of solutions for infusion;
- annually growth rate more than 40%;
- more than 100 items in the product line;
- total headcount (employees) more than 800;
- annual turnover up to 60 million units;
- exports to 9 countries;
- 80% of annual net profit is invested in modernization of production;
- each year about 10 new medical preparations are delivered;
- system quality control ISO 9001 : 2009 operates;
- GMP-certified manufacturing.

«YURiA-PHARM» Corporate Philosophy

OUR DESIGNATION

Life is the main global value!

Our main target is to protect and improve it!

OUR MISSION

- We create unique medications for human treatment and recovery.
- Through our patented technologies, we bring innovations in infusion therapy and set the style in pharmaceutical business.
- We achieve recognition of the Society, Physicians and Patients.
- We apply creative power of our Employees and Partners and promote their welfare.

OUR VISION

«YURiA-PHARM» is a leading innovational pharmaceutical corporation in Ukraine, the best employer in industry.

OUR VALUES

1. Our clients and partners who trust us.
2. We are ambitious professional team united with common corporate spirit.
3. The best quality of:
 - our products;
 - relationships with our Clients;
 - internal communications based on high ethical standards.
4. Maximum outcome and high business profitability.
5. Self-realization of every Employee.



REOSORBILACT®



Number One
infusion therapy drug

Ukraine's
research
heritage



2009

How supplied:
200 ml and 400 ml glass bottles.

REOSORBILACT® is a polyfunctional hyperosmolar drug. The rational combination of components that complement and potentiate each other allows achieving a polyfunctional effect: hemodynamics stabilization, pronounced detoxication effect, improved microcirculation and blood rheological properties, hydro-electrolytic

balance correction, mild metabolic acidosis correction, hepatoprotective action. REOSORBILACT® is the foundation of low-volume infusion therapy, a modern branch of internal medicine.

LATREN®



Enhanced
microcirculatory
effect

How supplied:
100 ml and 200ml glass bottles.

LATREN® is an infusion solution with a balanced isoosmolar electrolyte solution (Ringer's lactate solution) which potentiates the effect of pentoxifylline. Effective for both peripheral and brain circulation disorders.

LATREN® is supplied as a final dosage form, therefore eliminating the risk of technical error or solution infection.

SODA-BUFER®



Buffered sodium hydrocarbonate solution

How supplied:
100 ml, 200 ml and 20 ml glass bottles.

The use of SODA-BUFER® is recommended for diseases and pathological conditions accompanied with metabolic acidosis. Unlike regular baking soda (4.2% sodium carbonate) with a pH of 8.3-11.0, SODA-BUFER®, due to a patented CO₂ solution buffering technology, has a pH of 7.3-7.8, which

is physiological for the human body. This ensures exceptional safety of this drug.

The use of SODA-BUFER® of 20 ml is recommended for correction of pH of acid infusion solutions, makes an angioprotective effect and also minimize a bad senses of patient during protracted infusion therapy.

XYLAT®



Infusion therapy for diabetes mellitus and ketosis of different genesis

How supplied:
200 ml and 400 ml glass bottles.

A multicomponent hyperosmolar solution containing xylytol, sodium acetate and a balanced electrolyte complex. Has antiketogenic, nitrogenpreserving and lipotropic action. Xylytol is a pentabasic alcohol with insulinindependent utilization that does not influence the blood glucose level and

facilitates secretion of endogenic insulin. Of all carbohydrates and polyalcohols, xylytol has the most pronounced antiketogenic action. Sodium acetate is a slow-acting alkalizing agent that ensures acidosis correction without sharp pH level fluctuations. Due to the balanced electrolyte complex, the drug ensures correction of electrolyte imbalances. XYLAT® is an effective solution for cases of sugar diabetes and ketosis of different genesis.



TIVORTIN®



Indispensable
nitric oxide
donor

How supplied:

4.2% infusion solution in 100 ml glass bottles.

The active ingredient of TIVORTIN® is the L-arginine aminoacid, the only substrate used for nitric oxide (NO) synthesis in the human body. **TIVORTIN® is a physiological vasodilator** and vascular tone regulator. **TIVORTIN® is a physiological angioprotector:**

- decreases leukocyte activation and adhesion to endothelium;
- inhibits thrombocyte adhesion, activation and aggregation;
- inhibits adhesion protein synthesis;
- prevents pathologic vascular wall remodeling and atherosclerosis progression.

TIVORTIN® ASPARTATE



Indispensable nitric oxide
donor

How supplied:

oral solution in 100 ml and 200 ml.

TIVORTIN® ASPARTATE oral solution is part of a switch therapy with NO donors and ensures:

- maintained high clinic effectiveness of the therapy;
- shorter in-patient treatment time;
- possibility to continue treatment at home.

TIVORTIN® ASPARTATE contains the L-arginine aminoacid, an indispensable NO donor, and aspartic acid. Can be used for patients with concurrent diabetes mellitus.

GIK®



Ready form
of polarizing
solution

How supplied:

100 ml and 200 ml glass bottles.

GIK® provides the transport of glucose in cardiomyocytes, stimulates a synthesis of ATP, regulates a transmembrane transport of ions of K^+ , Na^+ , Ca^{2+} .

GIK® normalizes metabolism of myocardium in the conditions of ischemia: provides a heart glucose and reduces oxidization of fat acids,

has antiarrhythmic action, lowers the heightens sensitivity to cardiac glycosides and decreases their cardiotoxic effect.

GIK® is supplied as a final dosage form, therefore eliminating the risk of technical error or solution infection.

HEKODES®

Cost-efficient antishock
therapy



How supplied:

200 and 400 ml glass bottles; 500 ml polymer containers.

6% HES solution 200/0.5; volemic effect of 85-100%.

HEKODES® is a plasma substitute with pronounced volemic effect, high acceptability and additional specific advantages (lowers the «capillary loss» rate).

HEKODES® is a **cost-efficient antishock therapy** (the most affordable HES solution in Ukraine)



SORBILACT®



Hyperosmolar complex infusion solution

- stimulation of intestinal peristaltics
- treatment of intracranial hypertension

How supplied:
200 ml and 400 ml glass bottles.

SORBILACT® — a prophylaxis and treatment of enteroplegias are in an early postoperative period. SORBILACT® stimulates intestinal peristaltic mildly and efficiently; it can be applied starting from the 1-2nd day after surgery. The intestinal motility stimulation mechanism is based on the direct influence of the drug on the neuroreceptor apparatus of the intestines, increase of mesenteric circulation and stimulation of villikinine and cholecystokinine synthesis.

SORBILACT's additional osmодиuretic action provides maximal effect at therapy of cerebral edema. The presence of the balanced electrolyte composition diminishes the losses of electrolytes and does not create a "rebound" effect.

SORBILACT® — effective hemodynamic preparation which quickly removes hypovolemia and increases SAP and CPP.

AMINOCAPRONIC ACID, 5% solution

Hemostatic preparation



How supplied:
100 ml glass bottles;

SODIUM CHLORIDE 0,9% solution



How supplied:
100, 200 and 400 ml glass bottles;
containers of polymer 100, 200, 250, 500, 1000, 2000,
3000, 5000 ml.

WATER FOR INJECTIONS



How supplied:
100, 200 and 400 ml glass bottles;
100, 200, 250, 500, 1000, 2000,
3000, 5000 ml polymer containers

GLUCOSE 5% solution



How supplied:
200 ml and 400 ml glass
bottles.

POTASSIUM CHLORIDE

Concentrate
for solution
for infusion
7,5%



How supplied:
10 ml and 20 ml vials.



RINGER'S SOLUTION



How supplied:
200 ml and 400 ml glass bottles;
250 ml and 500 ml containers.

RINGER'S LACTATE SOLUTION



How supplied:
200 ml and 400 ml glass bottles;
containers 100, 200, 500 and 1000 ml.

SODIUM HYDROCARBONATE 4% solution



How supplied:
100 ml and 200 ml glass bottles.

MANNIT, 15% solution



How supplied:
200 ml and 400 ml glass bottles.

POLYGLUCINUM solution



How supplied:
200 ml and 400 ml glass bottles.

RHEOPOLYGLUCINUM solution



How supplied:
200 ml and 400 ml glass bottles.



DECASAN®



The most effective antiseptic solution

How supplied:

100 ml, 200 ml, 400 ml glass bottles; 1000 ml polybags, 2 ml and 4 ml containers.

DECASAN® – antiseptic solution for external and endocavitary application. 1 ml of solution contains 0.2 mg of decamethoxyn. One of the most important advantages of DECASAN® is the fact that it affects only bacterial cells, and not the cells of the human body. Additionally, it has anti-inflammatory, desensitizing and spasmolytic effect, which makes

it a good choice for treatment of bacterial and fungal skin diseases, microbial eczema, pyoinflammatory soft tissue involvement, dental diseases, inflammatory respiratory diseases, treatment of wounds, peritoneal commissures prevention, efficient prophylaxis and treatment of bedsores and trophic ulcers. DECASAN® is also highly effective for inhalation treatment.

HOROSTEN®



Protect yourself!

How supplied:

400 ml polymer bottle, 30 ml and 100 ml spray.

Active component – decamethoxyne, a widely known highly effective antiseptic.

Auxiliary components:

- Glycerin – softens and moisturizes the skin.
- Citral – stimulates a tissues reparation and gives a lemon aroma.

• 15% alcohol – does not dry out the skin, but ensures quick drying of the solution.

A wide range of antibacterial, antiviral, antifungal and antiprotozoal effect. The absence of an allergenic effect is ensured by the desensitizing effect of decamethoxyne.

LEFLOCIN®

The gold standard of empiric antibiotic therapy.
The safety standard of fluoroquinolones.



How supplied:
500 mg/100 ml glass bottles, 500 mg tablets, 10 tablets in a blister.

III generation of fluoroquinolones antibacterial drug.

The clinical and economic advantages of levofloxacin over other groups of antibacterial drugs has been scientifically proved in treatment of infections of different etiology and localization.

Unique mechanism of action provides the expressed bactericidal effect and minimum risk of resistance development.

Levofloxacin is recognized as one of the most safe antibacterial medications of available today.

LEFLOCIN® 750

The shortest path to the goal!



How supplied:
750 mg/150 ml glass bottles.

Short high-dosage treatment by levofloxacin (750 mg once daily, during 5 days) is officially approved for patients aged over 18 with community-acquired pneumonia, acute bacterial sinusitis, as well as aggravated urinary infections and acute pyelonephritis. 750 mg of levofloxacin in one vial ensures the best treatment effects in record-breaking time.



BIGAFLON®



The proper
gatifloxacin

How supplied:

400mg/100ml and 800mg/200ml glass bottles, 400 mg tablets, 10 tablets in blister.

BIGAFLON® is a IV generation fluoroquinolone. Its wide range of effect, including gram-negative, gram-positive, atypical and anaerobic microgerms, ensures highly effective treatment of virulent diseases regardless of their etiology.

BIGAFLON's effectiveness and safety are tested by many years of clinical application and the reputation of its manufacturer — YURIA-PHARM, the leader of the Ukrainian market of infusion drugs.

OFLOXACIN



How supplied:

200 mg/100 ml and 400 mg/200 ml glass bottles.

Quick and reliable antibacterial therapy for a wide range of infections.

MAXICIN®

More powerful!



How supplied: 400 mg/20 ml concentrate for preparation of infusion solution in dark glass vials with a solvent in a complete set

MAXICIN® (moxifloxacin) – is the newest fluoroquinolone of IV generation.

Combining all positive properties of previous fluoroquinolones, MAXICIN® possesses the wide spectrum of bactericidal action, good tolerance, minimum risk of resistance development.

The dark glass vials protect preparation from ultraviolet rays influence.

A presence in the complete set of solvent with the SOLUVEN™ system provides an exceptional quickness, comfort and safety of preparation of solution.

SOLUSEPTOL®

Co-trimoxazole syrup - as effective as an intravenous drug!



How supplied: syrup, 4 ml of which contains: 100 mg of sulphamethoxazole and 20 mg of trimethoprim; in 100 ml and 200 ml bottles.

SOLUSEPTOL® ensures consistent peak plasma concentration levels that approximate those achieved by the intravenous solution, and has an elimination half-life of a tablet drug.

Co-trimoxazole is the drug of choice for treatment and prevention of urinary infections, HIV/AIDS-associated infections (pneumocystic pneumonia, toxoplasmosis) and infectious diarrheas. Co-trimoxazole is included into the British National Formulary and the WHO Formulary.

SOLUSEPTOL® is a highly effective and pharmaco-economically favorable alternative to linezolid, clindamycin and vancomycin for treatment of infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA).

ORNIGIL®



Already not a metronidazole!

How supplied:

500 mg/100 ml and 1000 mg/200 ml glass bottles; 500 mg tablets, 10 tablets in a blister.

ORNIGIL® (ornidazole)

- No cross-resistance with metronidazol.
- Side effect occurrence rate does not exceed 3.7%.
- Effectiveness for treatment of trichomoniasis and prostatitis is 98.5%.
- Powerful bactericidal action against wide spectrum of anaerobes;

- Most corresponds to the requirements posed to preparation for a perioperative prophylaxis and treatment of surgical infections;
- Long half-life period provides high effectiveness of therapy in administration regimen 1000 mg once daily or 500 mg twice daily.

CIPROFLOXACIN



How supplied:

200 mg/100 ml glass bottles,
400 mg/200 ml containers.

Highly effective antibacterial drug for treatment of infectious diseases of various origin.

HYALUAL®-ARTRO

Move without pain!
A unique decision for
patients with
osteoarthritis



How supplied:

1.1% and 1.8% in pre-filled 1 ml and 2 ml syringes, with additionally supplied needles for intraarticular injection.

HYALUAL®-ARTRO is a preparation for intraarticular injection, which has the opportunity to influence on pathogenetic mechanisms of progressing of osteoarthritis.

The first component of a preparation - Hyaluronic acid has an anaesthetic and antiinflammatory actions and improves the

functional state of joints and quality of life of patient.

The second component of a preparation - Sodium succinate has a pathogenetic effects. It normalizes the intracellular metabolism of the hondrocytes, stimulates a synthesis of intracellular matrix of a cartilage, has an antioxidative action.

All these effects of sodium succinate allow to increase life-span of cartilage tissue and actively fights for the postponement of endoprothesis setting.



LACTUVIT®

A natural laxative that normalizes the intestinal function

LACTUVIT® is a physiological and safe regulator of a bowel motor function. It ensures bowel evacuation and softens a bowels content. It results to the correction of chronic lock practically of any its form. Thus does not render meaningful side effects and does not cause getting used.

The acting mechanism of LACTUVIT® is similar to that of food fiber. It creates an ideal nutritive medium for beneficial bifidus bacteria and lactic acid bacilli. It assists renewal of normal balance of microflora.

In case of hepatic encephalopathia LACTUVIT® decreases concentration of ammonia in the blood due to diminishing of its receipt from bowels. Lactuvite decreases bowels pH, hinders to reproduction of bacteria and suction of ammonia and other toxins.



How supplied:
100 ml and 200 ml bottles.

TIVORTIN® ASPARTATE

Indispensable
nitric oxide donor

The active ingredient of TIVORTIN® ASPARTATE is the L-arginine amino acid, the only substrate used for nitrogen oxide (NO) synthesis in the human body.

TIVORTIN® is a physiological vasodilator, a vascular tone regulator in normal conditions and as response to various stimuli.

TIVORTIN® is a physiological angioprotector:

- decreases leukocyte activation and adhesion to endothelium;
- inhibits thrombocyte aggregation and parietal thrombosis;
- inhibits vessel smooth muscle proliferation and pathologic vascular wall remodeling.

All of the above contributes to normalization of the endothelium function and prevention of

atherosclerosis occurrence and progression. The pharmaceutical form – oral solution – ensures dosage accuracy and convenient administration. TIVORTIN® ASPARTATE can be used for patients with concurrent diabetes mellitus.

TIVORTIN® ASPARTATE oral solution is part of a switch therapy with NO donors and ensures:

- maintained high clinic effectiveness of the therapy;
- shorter in-patient treatment time;
- possibility to continue treatment at home.



How supplied:
oral solution in 100 ml and 200 ml bottles.



ISONIAZID syrup



Protect your child from tuberculosis!

How supplied:

100 ml and 200 ml bottles.

The pharmaceutical form – a syrup – is used for the most effective and safe treatment and chemical prophylaxis of tuberculosis for diseased and infected children with BCG vaccination complications, as well as for those who had come in contact with tuberculosis patients.

The accurate dosing of syrup ensures treatment and prophylaxis effectiveness and prevents side effects.

1 ml of Isoniazid syrup contains 20 mg of isoniazid.

RIFONAT®

The most effective pharmaceutical form of the most effective drug!



How supplied:

Infusion solution concentrate 30 mg/ml. 5, 15 and 20 ml vials (150, 450 and 600 mg of Rifamycin accordingly). 15 ml and 20 ml vials (450 and 600 mg of Rifamycin accordingly) complete with a solvent.

Intravenous form of Rifamycin. First-line antituberculosis drug. Intravenous administration of RIFONAT® provides 100% bioavailability and creates maximum concentrations of preparation in blood and tissues.

In this way the highest efficiency of treatment is ensured along with minimizing the risk of development of MTB resistance. Inhalation application is possible.

INBUTOL®

Control and effectiveness!



How supplied:

10% solution in 10 ml and 20 ml vials.

Intravenous form of Ethambutol. First-line antituberculosis drug. Resistance of bacillus Kochii to INBUTOL® develops slowly. The use of INBUTOL® (bioavailability of 100%) instead of a tablet form of ethambutol (bioavailability of 77%) during inpatient treatment allows to decrease the administered dose

while maintaining high treatment effectiveness. Decreasing the ethambutol dosage lowers the risk of tuberculosis polychemotherapy side effects.

PASKONAT®

Time-tested tuberculosis treatment



How supplied:

12 g/400 ml glass bottles.

PASKONAT® is used mainly for treatment of tuberculosis form that had not responded to earlier therapy, recurrent diseases, forms resistant to the main antituberculosis drugs, and in cases of patient intolerance to drugs. Using PASKONAT® in comprehensive

tuberculosis treatment allows enhancing the effect of other antituberculosis drugs and slow down the development of the bacillus Kochii resistance to the drugs.



METRONIDAZOLE

Antibacterial antiprotozoal drug for systemic administration



How supplied:
500 mg/100 ml glass bottles.

NOVOCAINE 0,25% and 0,5% solution



How supplied:
200 ml and 400 ml glass bottles.

AMINOL®



How supplied:
100, 200 and 400 ml glass bottles.

A balanced complex of L-forms of dispensable and indispensable aminoacids for parenteral nutrition.

GLUXYL®

The basis of effective parenteral nutrition:
optimal source of carbohydrates necessary for amino-acids assimilation



How supplied:
200 ml and 400 ml glass bottles.

GLUXYL® is a carbohydrate component of parenteral feeding. Contains xylytol, glucose, sodium acetate and a balanced complex of electrolytes. Quickly absorbed in patients with normal metabolism and under stress (xylytol enhances glucose utilization) and does not increase the blood plasma lactate,

pyruvate and glucose levels. One of the obligatory conditions for effective parenteral nutrition is the concurrent administration of plastic material donors (amino-acids) and energy donors (GLUXYL®).



AKK®

A reliable barrier against flu and cold!

AKK® has an evident antiviral action, prevents contamination and blocks virus propagation. AKK® hampers penetration of flu A and B viruses, herpes, RS-virus, adenovirus and arbovirus in human cells.

AKK® improves the cellular and humoral indexes of specific and nonspecific defence of organism in case of ARVI.

AKK® strengthens an immune answer during immunization by influenzal vaccines.

For the purpose of flu and ARVI prophylaxis AKK should be used intranasally 2-3 drops 4-5 times a day; For purpose of treatment – every 3 hours.

Course of treatment lasts 3-7 days.

The drug is suitable for newborns.



How supplied:
10 disposable containers of 2 and 5 ml.

FLUCONAZOLE

The most effective antifungal drug



How supplied:

100 mg/50 ml and 200 mg/100 ml vials.

Fluconazole is the drug of choice for fungal infections of various localization caused by *Candida* fungi, including candidemia.

The prolonged elimination half-life of the drug – 30 hours – allows to administer it only once daily.

Intravenous administration of fluconazole ensures high effectiveness against fungal infections of various localization, minimal treatment duration for acute uncomplicated disease forms, and a high anti-relapse effect.

FLUCONAZOLE 400 mg

A unique decision of the problem of fungal infections



How supplied:

400 mg/200 ml vials.

Most effective in case of:

- severe hospital fungal infections;
- fungal infections in intensive care unit patients;
- systemic candidosis (including fungemia);
- opportunistic fungal infections in patients with HIV/AIDS;

- generalized fungal infections in oncologic patients concurrent with chemo- and roetgen therapy.
- fungal infections caused by resistant fungi.



TURUSOL®



Non-hemolizing
solution for
endoscopy

How supplied:
1000 ml, 3000 ml and 5000 ml polymer containers.

1000 ml of solution contains:
Sorbitol - 27 g, Mannitol - 5,4 g in water for injections.

Turusol corresponds to the requirements posed to irrigation solutions:

- does not contain electrolytes;
- osmotically adapted;

- optically translucent;
- sterile, apyrogenic, constant composition (official)

Turusol is used as irrigation solution during realization of endoscopic diagnostic and surgical interferences in urology, gynecology, orthopaedia-traumatology (TURP, hysteroscopy, arthroscopy etc.).

DECASAN - CYTOCLIN™



How supplied:
1000 ml polymer containers.

Antiseptic irrigation solution

CYTOCLIN™



Sodium chloride-Cytoclin sol., Glukose-Cytoclin sol., Ringer's-Cytoclin sol., Ringer's lactate-Cytoclin sol., Decasan-Cytoclin sol.
 How supplied: 1000 ml, 2000 ml, 3000 ml and 5000 ml polymer containers.

CYTOCLIN™ is a system for irrigation and washing.


CYTOCLIN™ solutions are produced in high-volume polymeric containers: 500, 1000, 2000, 3000 and 5000 ml, which is an additional factor,

providing comfort and safety of use both in in-patient cases and in extreme situations.

Used as an irrigational liquid during endoscopic manipulations, washing of cavities, and also for washing of medical equipment.



SOLUVEN™



Sodium chloride-Soloven sol., Glukose-Soloven sol., Ringer's-Soloven sol., Ringer's lactate-Soloven sol.
How supplied: 50 ml, 100 ml, 200 ml and 400 ml polymer containers

SOLUVEN™ is a closed system for drugs reconstitution.

The feature of the system is emergency safety, comfort, simplicity and quickness of process of infusion solutions preparing.

SOLUVEN™ system eliminates possibility of hit of medical preparation in an external environment, contact of personnel or patient with it.

SOLUVEN™ systems made from polymeric materials, that is the additional factor of providing of safety of the use both in hospital conditions and in extreme situations on the outpatient stage of medicare.

SYRINGES YURiA-PHARM WITH TWO NEEDLES

Unique high quality patented 3-component syringes with two needles

Yuria-Pharm 3-component syringes are supplied with 2 needles of different size:

- the larger needle is attached to the syringe and is recommended for the intake of the medication solution from the container;
- the smaller needle, supplied with the syringe, is recommended for the injection.

Using the Yuria-Pharm syringes supplied with two different-sized needles ensures:

- maintaining sterility during injection;
- the option to choose the suitable needle diameter;
- the option to use a smaller diameter needle for injections for children;
- the option to use the larger diameter needle for easier intake of



the medication solution;

- the option to perform the injection with a sharp needle, and not the one that was used for the intake of the medication solution;
- cost saving when purchasing a syringe with two needles compared to a separate purchase of a one-needle syringe and an extra needle.

I.V. SETS YURiA-PHARM



1. Infusion systems are used for administration of solutions;

2. Transfusion systems are used for blood and blood component transfusions.



A series of horizontal dotted lines for writing notes, organized into two columns.

Handwriting practice area with two columns of 15 dotted lines each.





YURiA-PHARM LTD
10, Amosova street, Kyiv, Ukraine,
03680
tel/fax: +38 (044) 246-8191, 246-8383
www.uf.ua



*Leader of intravenous drugs
market in Ukraine and CIS*

ISO 9001:2009